HK1113569A1 - Pyrazolo - Google Patents

Pyrazolo

Info

Publication number: HK1113569A1
Authority: HK; Hong Kong
Prior art keywords: compounds; compositions; pyrazolo; provides; disorders
Prior art date: 2004-11-04

Application number

HK08102917.8A

Other languages

English (en)

Inventor

Jimenez J Juan-Miguel

Ronald Knegtel

Charrier J Jean-Damien

Dean Stamos

Li Pan

Jon R Come

Alex Aronov

Original Assignee

Vertex Pharma

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2004-11-04

Filing date

2008-03-13

Publication date

2008-10-10

2008-03-13 Application filed by Vertex Pharma filed Critical Vertex Pharma

2008-10-10 Publication of HK1113569A1 publication Critical patent/HK1113569A1/xx

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/08—Antiseborrheics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/10—Anti-acne agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/14—Drugs for dermatological disorders for baldness or alopecia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
- A61P21/04—Drugs for disorders of the muscular or neuromuscular system for myasthenia gravis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/16—Otologicals
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/18—Antivirals for RNA viruses for HIV
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/04—Immunostimulants
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
- C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
- C07F9/02—Phosphorus compounds
- C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
- C07F9/6561—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom containing systems of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring or ring system, with or without other non-condensed hetero rings

Landscapes

Health & Medical Sciences (AREA)
Chemical & Material Sciences (AREA)
Organic Chemistry (AREA)
Life Sciences & Earth Sciences (AREA)
General Health & Medical Sciences (AREA)
Veterinary Medicine (AREA)
Public Health (AREA)
Animal Behavior & Ethology (AREA)
Medicinal Chemistry (AREA)
Pharmacology & Pharmacy (AREA)
General Chemical & Material Sciences (AREA)
Chemical Kinetics & Catalysis (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Bioinformatics & Cheminformatics (AREA)
Engineering & Computer Science (AREA)
Immunology (AREA)
Dermatology (AREA)
Diabetes (AREA)
Pulmonology (AREA)
Molecular Biology (AREA)
Cardiology (AREA)
Obesity (AREA)
Hematology (AREA)
Orthopedic Medicine & Surgery (AREA)
Physical Education & Sports Medicine (AREA)
Biochemistry (AREA)
Heart & Thoracic Surgery (AREA)
Neurology (AREA)
Rheumatology (AREA)
Virology (AREA)
Transplantation (AREA)
Neurosurgery (AREA)
Oncology (AREA)
Pain & Pain Management (AREA)
Tropical Medicine & Parasitology (AREA)
Ophthalmology & Optometry (AREA)
Child & Adolescent Psychology (AREA)
Biomedical Technology (AREA)
AIDS & HIV (AREA)
Communicable Diseases (AREA)

HK08102917.8A 2004-11-04 2008-03-13 Pyrazolo HK1113569A1 (en)

Applications Claiming Priority (2)

Application Number	Priority Date	Filing Date	Title
US62544604P	2004-11-04	2004-11-04
PCT/US2005/040344 WO2006052913A1 (en)	2004-11-04	2005-11-04	PYRAZOLO[1,5-a]PYRIMIDINES USEFUL AS INHIBITORS OF PROTEIN KINASES

Publications (1)

Publication Number	Publication Date
HK1113569A1 true HK1113569A1 (en)	2008-10-10

Family

ID=35809833

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
HK08102917.8A HK1113569A1 (en)	2004-11-04	2008-03-13	Pyrazolo

Country Status (21)

Country	Link
US (1)	US7528138B2 (ja)
EP (1)	EP1812440B1 (ja)
JP (2)	JP5030229B2 (ja)
KR (1)	KR20070090172A (ja)
CN (1)	CN101094853B (ja)
AT (1)	ATE482213T1 (ja)
AU (1)	AU2005304784B2 (ja)
CA (1)	CA2586375A1 (ja)
DE (1)	DE602005023763D1 (ja)
DK (1)	DK1812440T3 (ja)
ES (1)	ES2354824T3 (ja)
HK (1)	HK1113569A1 (ja)
IL (1)	IL182893A0 (ja)
MX (1)	MX337817B (ja)
NO (1)	NO20072795L (ja)
NZ (1)	NZ555236A (ja)
PT (1)	PT1812440E (ja)
RU (1)	RU2417996C2 (ja)
SI (1)	SI1812440T1 (ja)
WO (1)	WO2006052913A1 (ja)
ZA (1)	ZA200704476B (ja)

Families Citing this family (103)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
SE0104140D0 (sv) *	2001-12-07	2001-12-07	Astrazeneca Ab	Novel Compounds
ATE482213T1 (de) *	2004-11-04	2010-10-15	Vertex Pharma	Als inhibitoren von proteinkinasen geeignete pyrazoloä1,5-aüpyrimidine
EP1853588B1 (en) *	2005-02-16	2008-06-18	AstraZeneca AB	Chemical compounds
EP1881986A2 (en) *	2005-05-12	2008-01-30	Merck & Co., Inc.	Tyrosine kinase inhibitors
WO2006123113A2 (en) *	2005-05-16	2006-11-23	Astrazeneca Ab	Pyrazolylaminopyrimidine derivatives useful as tyrosine kinase inhibitors
WO2007046867A2 (en) *	2005-05-19	2007-04-26	Xenon Pharmaceuticals Inc.	Piperidine derivatives and their uses as therapeutic agents
MX2007014619A (es) *	2005-05-20	2009-02-13	Vertex Pharma	Pirrolopiridinas de utilidad como inhibidores de proteina quinasa.
JP2009513615A (ja) *	2005-10-28	2009-04-02	アストラゼネカアクチボラグ	癌の治療においてチロシンキナーゼ阻害剤として使用するための４−（３−アミノピラゾール）ピリミジン誘導体
ES2611588T3 (es)	2005-12-13	2017-05-09	Incyte Holdings Corporation	Pirrolo[2,3-b]piridinas y pirrolo[2,3-b]pirimidinas sustituidas con heteroarilo como inhibidores de quinasas Janus
GB0601638D0 (en) *	2006-01-27	2006-03-08	Merck Sharp & Dohme	Therapeutic treatment
US8198448B2 (en)	2006-07-14	2012-06-12	Amgen Inc.	Fused heterocyclic derivatives and methods of use
US8217177B2 (en)	2006-07-14	2012-07-10	Amgen Inc.	Fused heterocyclic derivatives and methods of use
PE20121506A1 (es) *	2006-07-14	2012-11-26	Amgen Inc	Compuestos triazolopiridinas como inhibidores de c-met
CA2668286C (en) *	2006-11-03	2014-09-16	Pharmacyclics, Inc.	Bruton's tyrosine kinase activity probe and method of using
CA2681516A1 (en) *	2007-03-22	2008-09-25	Vertex Pharmaceuticals Incorporated	Compounds useful as inhibitors of janus kinases
CN101679429A (zh) *	2007-04-18	2010-03-24	阿斯利康(瑞典)有限公司	5-氨基吡唑-3-基-3h-咪唑并[4,5-b]吡啶衍生物及其治疗癌的用途
UA99459C2 (en) *	2007-05-04	2012-08-27	Астразенека Аб	9-(pyrazol-3-yl)- 9h-purine-2-amine and 3-(pyraz0l-3-yl)-3h-imidazo[4,5-b]pyridin-5-amine derivatives and their use for the treatment of cancer
US20100204231A1 (en) *	2007-05-04	2010-08-12	Astrazeneca Ab	Amino-thiazolyl-pyrimidine derivatives and their use for the treatment of cancer
LT3070090T (lt)	2007-06-13	2019-06-25	Incyte Holdings Corporation	Janus kinazės inhibitoriaus (r)-3-(4-(7h-pirol[2,3-d]pirimidin-4-il)-1h-pirazol-1-il)-3-ciklopentilpropannitrilo druskų panaudojimas
CN101878217B (zh)	2007-09-28	2014-01-15	协和发酵麒麟株式会社	皮肤疾病的预防和/或治疗剂
ES2569528T3 (es) *	2007-11-16	2016-05-11	Incyte Holdings Corporation	4-pirazolil-N-arilpirimidin-2-aminas y 4-pirazolil-N-heteroarilpirimidin-2-aminas como inhibidores de quinasas Janus
JP5520831B2 (ja) *	2007-12-19	2014-06-11	アムジエン・インコーポレーテツド	Ｐｉ３キナーゼの阻害薬
MX2010006748A (es) *	2007-12-19	2010-08-18	Vertex Pharma	Pirazolo[1,5-a]pirimidinas utiles como inhibidores de jak2.
CA2718403A1 (en) *	2008-03-13	2009-09-17	The General Hospital Corporation	Inhibitors of the bmp signaling pathway
BRPI0915101A2 (pt) *	2008-06-11	2017-03-21	Astrazeneca Ab	composto, uso do mesmo, método para tratar câncer em um animal de sangue quente, composição farmacêutica, e, processo para preparar um composto
US8394802B2 (en) *	2008-09-19	2013-03-12	Nerviano Medical Sciences S.R.L.	3,4-dihydro-2H-pyrrolo[1,2-a]pyrazin-1-one derivatives for the modulation of the activity of protein kinases
CA2738026C (en)	2008-09-22	2017-01-24	Array Biopharma Inc.	Substituted imidazo[1,2b]pyridazine compounds as trk kinase inhibitors
EP2346859A1 (en) *	2008-09-30	2011-07-27	AstraZeneca AB	Heterocyclic jak kinase inhibitors
MX2011004494A (es) *	2008-10-31	2011-05-24	Genentech Inc	Compuestos de pirazolopirimidina inhibidores de jak y metodos.
GB0821913D0 (en)	2008-12-02	2009-01-07	Price & Co	Antibacterial compounds
US8604043B2 (en)	2009-05-22	2013-12-10	Incyte Corporation	3-[4-(7H-pyrrolo[2,3-D]pyrimidin-4-yl)-1H-pyrazol-1-yl]octane- or heptane-nitrile as jak inhibitors
WO2010135650A1 (en) *	2009-05-22	2010-11-25	Incyte Corporation	N-(HETERO)ARYL-PYRROLIDINE DERIVATIVES OF PYRAZOL-4-YL-PYRROLO[2,3-d]PYRIMIDINES AND PYRROL-3-YL-PYRROLO[2,3-d]PYRIMIDINES AS JANUS KINASE INHIBITORS
AU2010254063A1 (en) *	2009-05-28	2011-12-01	Vertex Pharmaceuticals Incorporated	Inhibitors of c-Met protein kinase
BRPI1011993A2 (pt)	2009-06-17	2021-07-06	Vertex Pharmaceuticals Incorporated	inibidores de replicação do vírus influenza, seu uso, método de preparação dos mesmos e compositção farmacêutica que os compreende
UA110324C2 (en)	2009-07-02	2015-12-25	Genentech Inc	Jak inhibitory compounds based on pyrazolo pyrimidine
AR077468A1 (es)	2009-07-09	2011-08-31	Array Biopharma Inc	Compuestos de pirazolo (1,5 -a) pirimidina sustituidos como inhibidores de trk- quinasa
US9249145B2 (en)	2009-09-01	2016-02-02	Incyte Holdings Corporation	Heterocyclic derivatives of pyrazol-4-yl-pyrrolo[2,3-d]pyrimidines as janus kinase inhibitors
DK2473049T3 (en)	2009-09-04	2019-04-01	Biogen Ma Inc	INHIBITORS OF BRUTON'S TYROSINKINASE
EP4036088B1 (en)	2010-03-10	2024-04-03	Incyte Holdings Corporation	Piperidin-4-yl azetidine derivatives as jak1 inhibitors
US20130096160A1 (en) *	2010-04-14	2013-04-18	Secretary, Department Of Health And Human Services	Arylthiazolyl piperidines and related compounds as modulators of survival motor neuron (smn) protein production
AU2011254242B2 (en)	2010-05-17	2015-10-29	Incozen Therapeutics Pvt. Ltd.	Novel 3,5-disubstitued-3H-imidazo[4,5-b]pyridine and 3,5- disubstitued -3H-[1,2,3]triazolo[4,5-b] pyridine compounds as modulators of protein kinases
KR101852169B1 (ko)	2010-05-20	2018-04-26	어레이 바이오파마 인크.	Trk 키나제 저해제로서의 매크로시클릭 화합물
SG10201503983QA (en)	2010-05-21	2015-06-29	Incyte Corp	Topical Formulation for a JAK Inhibitor
BR112012030621B1 (pt)	2010-06-01	2020-10-27	Summit (Oxford) Limited	compostos para o tratamento de doença associada a clostridium difficile
GB2480814A (en) *	2010-06-01	2011-12-07	Summit Corp Plc	Compounds for the treatment of clostridium difficile-associated disease
CA2818545C (en)	2010-11-19	2019-04-16	Incyte Corporation	Heterocyclic-substituted pyrrolopyridines and pyrrolopyrimidines as jak inhibitors
BR112013012502A2 (pt)	2010-11-19	2019-03-06	Incyte Corporation	pirrolopiridina ciclobutil substituída e derivados de pirrolopirimidina derivativos como inibidores de jak
CA2822057A1 (en) *	2010-12-16	2012-06-21	Vertex Pharmaceuticals Incorporated	Inhibitors of influenza viruses replication
CN103814016B (zh) *	2011-06-10	2017-03-08	默克专利有限公司	生产具有btk抑制活性的嘧啶和吡啶化合物的组合物和方法
EP2721028B1 (en)	2011-06-20	2015-11-04	Incyte Corporation	Azetidinyl phenyl, pyridyl or pyrazinyl carboxamide derivatives as jak inhibitors
WO2012178125A1 (en)	2011-06-22	2012-12-27	Vertex Pharmaceuticals Incorporated	Compounds useful as inhibitors of atr kinase
UA118010C2 (uk)	2011-08-01	2018-11-12	Вертекс Фармасьютікалз Інкорпорейтед	Інгібітори реплікації вірусів грипу
TW201313721A (zh)	2011-08-18	2013-04-01	Incyte Corp	作為ｊａｋ抑制劑之環己基氮雜環丁烷衍生物
US9096605B2 (en) *	2011-08-24	2015-08-04	Glaxosmithkline Llc	Pyrazolopyrimidine derivatives as PI3 kinase inhibitors
UA111854C2 (uk)	2011-09-07	2016-06-24	Інсайт Холдінгс Корпорейшн	Способи і проміжні сполуки для отримання інгібіторів jak
KR20140144726A (ko)	2012-03-30	2014-12-19	리젠 파마슈티컬스 소시에떼 아노님	C-met 단백질 키나제의 조절제로서의 신규한 3,5-디치환-3h-이미다조[4,5-b]피리딘 및 3,5- 디치환 -3h-[1,2,3]트리아졸로[4,5-b] 피리딘 화합물
WO2013173720A1 (en)	2012-05-18	2013-11-21	Incyte Corporation	Piperidinylcyclobutyl substituted pyrrolopyridine and pyrrolopyrimidine derivatives as jak inhibitors
AR091273A1 (es)	2012-06-08	2015-01-21	Biogen Idec Inc	Inhibidores de pirimidinil tirosina quinasa
WO2014028829A1 (en) *	2012-08-16	2014-02-20	The Scripps Research Institute	Novel kappa opioid ligands
CN113384546A (zh)	2012-11-15	2021-09-14	因赛特公司	鲁索利替尼的缓释剂型
WO2014081996A1 (en) *	2012-11-23	2014-05-30	Glaxosmithkline Llc	Novel compounds as diacylglycerol acyltransferase inhibitors
SI3486245T1 (sl)	2012-12-07	2021-09-30	Vertex Pharmaceuticals Incorporated	2-amino-n-(piperidin-1-il-piridin-3-il)pirazolo(1,5alfa)pirimidin-3- karboksamid kot zaviralec atr kinaze
TW201501713A (zh) *	2013-03-01	2015-01-16	Kyowa Hakko Kirin Co Ltd	眼炎症性疾病之預防及／或治療劑
AR095018A1 (es)	2013-03-06	2015-09-16	Incyte Corp	Procesos e intermedios para hacer un inhibidor de jak
US9682983B2 (en)	2013-03-14	2017-06-20	The Brigham And Women's Hospital, Inc.	BMP inhibitors and methods of use thereof
EP2970286A1 (en)	2013-03-15	2016-01-20	Vertex Pharmaceuticals Inc.	Fused pyrazolopyrimidine derivatives useful as inhibitors of atr kinase
US8957078B2 (en)	2013-03-15	2015-02-17	Vertex Pharmaceuticals Incorporated	Compounds useful as inhibitors of ATR kinase
WO2014143242A1 (en) *	2013-03-15	2014-09-18	Vertex Pharmaceuticals Incorporated	Compounds useful as inhibitors of atr kinase
WO2014175370A1 (ja) *	2013-04-25	2014-10-30	塩野義製薬株式会社	ピロリジン誘導体およびそれらを含有する医薬組成物
US9655854B2 (en)	2013-08-07	2017-05-23	Incyte Corporation	Sustained release dosage forms for a JAK1 inhibitor
LT3421468T (lt)	2013-11-13	2021-01-11	Vertex Pharmaceuticals Incorporated	Gripo virusų replikacijos inhibitorių paruošimo būdai
JP6615755B2 (ja)	2013-11-13	2019-12-04	バーテックスファーマシューティカルズインコーポレイテッド	インフルエンザウイルスの複製の阻害剤
WO2015073267A1 (en) *	2013-11-15	2015-05-21	Calitor Sciences, Llc	Substituted heteroaryl compounds and methods of use
CN104650092B (zh) *	2013-11-16	2017-11-10	广东东阳光药业有限公司	取代的杂芳基化合物及其组合物和用途
KR102153886B1 (ko)	2013-12-06	2020-09-09	버텍스 파마슈티칼스 인코포레이티드	Atr 키나제 억제제로서 유용한 2-아미노-6-플루오로-n-[5-플루오로-피리딘-3-일]피라졸로[1,5-a]피리미딘-3-카복스아미드 화합물, 이의 제조 방법, 이의 상이한 고체형 및 방사성표지된 유도체
HUE054784T2 (hu)	2014-05-23	2021-09-28	Hoffmann La Roche	5-klór-2-difluor-metoxifenil-pirazolopirimidin vegyületek, amelyek JAK-gátlók
WO2015184305A1 (en)	2014-05-30	2015-12-03	Incyte Corporation	TREATMENT OF CHRONIC NEUTROPHILIC LEUKEMIA (CNL) AND ATYPICAL CHRONIC MYELOID LEUKEMIA (aCML) BY INHIBITORS OF JAK1
CA2950587C (en)	2014-06-05	2022-06-28	Vertex Pharmaceuticals Incorporated	Radiolabelled derivatives of a 2-amino-6-fluoro-n-[5-fluoro-pyridin-3-yl]- pyrazolo[1,5-a]pyrimidin-3-carboxamide compound useful as atr kinase inhibitor, the preparation of said compound and different solid forms thereof
NZ727399A (en)	2014-06-17	2022-07-29	Vertex Pharma	Method for treating cancer using a combination of chk1 and atr inhibitors
WO2016011019A1 (en)	2014-07-15	2016-01-21	The Brigham And Women's Hospital, Inc.	Compositions and methods for inhibiting bmp
TWI746426B (zh)	2014-11-16	2021-11-21	美商亞雷生物製藥股份有限公司	(S)-N-(5-((R)-2-(2,5-二氟苯基)-吡咯啶-1-基)-吡唑并[1,5-a]嘧啶-3-基)-3-羥基吡咯啶-1-甲醯胺硫酸氫鹽結晶型
EP3294735B8 (en)	2015-05-13	2022-01-05	Vertex Pharmaceuticals Incorporated	Inhibitors of influenza viruses replication
WO2016183116A1 (en)	2015-05-13	2016-11-17	Vertex Pharmaceuticals Incorporated	Methods of preparing inhibitors of influenza viruses replication
EP3355926A4 (en)	2015-09-30	2019-08-21	Vertex Pharmaceuticals Inc.	METHOD FOR THE TREATMENT OF CANCER WITH A COMBINATION OF DNA DAMAGING AGENTS AND ATR INHIBITORS
KR20180102544A (ko)	2015-10-26	2018-09-17	더 리전츠 오브 더 유니버시티 오브 콜로라도, 어 바디 코퍼레이트	Trk 억제제-내성 암에서의 점 돌연변이 및 이의 관련 방법
RS65987B1 (sr)	2016-04-04	2024-10-31	Loxo Oncology Inc	Tečne formulacije (s)-n-(5-((r)-2-(2,5-difluorofenil)-pirolidin-1-il)-pirazolo[1,5-]pirimidin-3-il)-3-hidroksipirolidin-1-karboksamida
US10045991B2 (en)	2016-04-04	2018-08-14	Loxo Oncology, Inc.	Methods of treating pediatric cancers
LT3458456T (lt)	2016-05-18	2021-02-25	Loxo Oncology, Inc.	(s)-n-(5-((r)-2-(2,5-difluorfenil)pirolidin-1-il)pirazolo[1,5-a]pirimidin-3-il)-3-hidroksipirolidin-1-karboksamido gavimas
AU2017299850B2 (en)	2016-07-18	2021-05-27	University Health Network	Solid forms of TTK inhibitor
AU2017298035B2 (en)	2016-07-21	2021-10-28	Biogen Ma Inc.	Succinate forms and compositions of Bruton's tyrosine kinase inhibitors
JOP20190092A1 (ar)	2016-10-26	2019-04-25	Array Biopharma Inc	عملية لتحضير مركبات بيرازولو[1، 5-a]بيريميدين وأملاح منها
JOP20190213A1 (ar)	2017-03-16	2019-09-16	Array Biopharma Inc	مركبات حلقية ضخمة كمثبطات لكيناز ros1
US11026947B2 (en)	2017-04-27	2021-06-08	The Brigham And Women's Hospital, Inc.	ALK2 inhibitors and methods for inhibiting BMP signaling
PL233595B1 (pl) *	2017-05-12	2019-11-29	Celon Pharma Spolka Akcyjna	Pochodne pirazolo[1,5-a]pirymidyny jako inhibitory kinazy JAK
US10307426B2 (en)	2017-05-22	2019-06-04	Genentech, Inc.	Therapeutic compounds and compositions, and methods of use thereof
WO2019113487A1 (en)	2017-12-08	2019-06-13	Incyte Corporation	Low dose combination therapy for treatment of myeloproliferative neoplasms
IL301089A (en) *	2018-01-29	2023-05-01	Vertex Pharma	GCN2 inhibitors and their uses
CA3089769A1 (en)	2018-01-29	2019-08-01	Merck Patent Gmbh	Gcn2 inhibitors and uses thereof
WO2019152374A1 (en)	2018-01-30	2019-08-08	Incyte Corporation	Processes for preparing (1 -(3-fluoro-2-(trifluoromethyl)isonicotinyl)piperidine-4-one)
HUE067471T2 (hu)	2018-03-30	2024-10-28	Incyte Corp	Gennyes verejtékmirigy-gyulladás kezelése jak inhibitorok alkalmazásával
AU2019364631A1 (en)	2018-10-26	2021-06-03	Keros Therapeutics, Inc.	Crystal forms of an ALK2 inhibitor
CR20210336A (es)	2018-12-20	2021-12-06	Incyte Corp	Compuestos de imidazopiridazina e imidazopiridina como inhibidores de quinasa-2 de tipo receptor de activina
US11833155B2 (en)	2020-06-03	2023-12-05	Incyte Corporation	Combination therapy for treatment of myeloproliferative neoplasms

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
CA2291709A1 (en)	1997-05-30	1998-12-03	Merck & Co., Inc.	Novel angiogenesis inhibitors
US6245759B1 (en) *	1999-03-11	2001-06-12	Merck & Co., Inc.	Tyrosine kinase inhibitors
GB0103926D0 (en)	2001-02-17	2001-04-04	Astrazeneca Ab	Chemical compounds
US7550470B2 (en) *	2002-12-11	2009-06-23	Merck & Co. Inc.	Substituted pyrazolo[1,5-A]pyrimidines as tyrosine kinase inhibitors
ATE482213T1 (de) *	2004-11-04	2010-10-15	Vertex Pharma	Als inhibitoren von proteinkinasen geeignete pyrazoloä1,5-aüpyrimidine

2005
- 2005-11-04 AT AT05816516T patent/ATE482213T1/de active
- 2005-11-04 DE DE602005023763T patent/DE602005023763D1/de active Active
- 2005-11-04 SI SI200531195T patent/SI1812440T1/sl unknown
- 2005-11-04 JP JP2007540144A patent/JP5030229B2/ja not_active Expired - Fee Related
- 2005-11-04 AU AU2005304784A patent/AU2005304784B2/en not_active Ceased
- 2005-11-04 KR KR1020077012308A patent/KR20070090172A/ko not_active Application Discontinuation
- 2005-11-04 RU RU2007120518/04A patent/RU2417996C2/ru not_active IP Right Cessation
- 2005-11-04 US US11/266,935 patent/US7528138B2/en not_active Expired - Fee Related
- 2005-11-04 PT PT05816516T patent/PT1812440E/pt unknown
- 2005-11-04 ES ES05816516T patent/ES2354824T3/es active Active
- 2005-11-04 NZ NZ555236A patent/NZ555236A/en not_active IP Right Cessation
- 2005-11-04 MX MX2007005439A patent/MX337817B/es active IP Right Grant
- 2005-11-04 EP EP05816516A patent/EP1812440B1/en active Active
- 2005-11-04 DK DK05816516.8T patent/DK1812440T3/da active
- 2005-11-04 CA CA002586375A patent/CA2586375A1/en not_active Abandoned
- 2005-11-04 CN CN2005800450252A patent/CN101094853B/zh not_active Expired - Fee Related
- 2005-11-04 ZA ZA200704476A patent/ZA200704476B/xx unknown
- 2005-11-04 WO PCT/US2005/040344 patent/WO2006052913A1/en active Application Filing
2007
- 2007-05-01 IL IL182893A patent/IL182893A0/en unknown
- 2007-06-01 NO NO20072795A patent/NO20072795L/no not_active Application Discontinuation
2008
- 2008-03-13 HK HK08102917.8A patent/HK1113569A1/xx not_active IP Right Cessation
- 2008-10-29 JP JP2008278235A patent/JP2009067803A/ja active Pending

Also Published As

Publication number	Publication date
CA2586375A1 (en)	2006-05-18
JP2008519059A (ja)	2008-06-05
AU2005304784B2 (en)	2011-03-24
KR20070090172A (ko)	2007-09-05
MX337817B (es)	2011-11-04
SI1812440T1 (sl)	2011-04-29
DK1812440T3 (da)	2011-01-31
NO20072795L (no)	2007-06-01
WO2006052913A1 (en)	2006-05-18
EP1812440A1 (en)	2007-08-01
RU2007120518A (ru)	2008-12-10
PT1812440E (pt)	2011-01-25
JP2009067803A (ja)	2009-04-02
US20060135537A1 (en)	2006-06-22
EP1812440B1 (en)	2010-09-22
ES2354824T3 (es)	2011-03-18
AU2005304784A1 (en)	2006-05-18
CN101094853A (zh)	2007-12-26
US7528138B2 (en)	2009-05-05
MX2007005439A (es)	2008-02-19
JP5030229B2 (ja)	2012-09-19
IL182893A0 (en)	2007-08-19
RU2417996C2 (ru)	2011-05-10
NZ555236A (en)	2010-10-29
CN101094853B (zh)	2011-07-13
DE602005023763D1 (de)	2010-11-04
ZA200704476B (en)	2008-09-25
ATE482213T1 (de)	2010-10-15

Publication	Publication Date	Title
HK1113569A1 (en)	2008-10-10	Pyrazolo
HK1096673A1 (en)	2007-06-08	Compositions useful as inhibitors of protein kinases
TW200633980A (en)	2006-10-01	Pyridones useful as inhibitors of kinases
HK1116349A1 (en)	2008-12-19	Pyrrolopyrimidines useful as inhibitors of protein kinase
SG166828A1 (en)	2010-12-29	Aminopyrimidines useful as kinase inhibitors
TW200604168A (en)	2006-02-01	Azaindoles useful as inhibitors of rock and other protein kinases
MX2009006345A (es)	2009-06-23	Compuestos utiles como inhibidores de proteina cinasa.
SG151327A1 (en)	2009-04-30	Deazapurines useful as inhibitors of janus kinases
MX2009006700A (es)	2009-06-30	Derivados de 5-ciano-4-(pirolo)[2,3b]piridina-3-il)-pirimidinas utiles como inhibidores de proteina-cinasas.
WO2005028475A3 (en)	2005-06-09	Compositions useful as inhibitors of protein kinases
MX2009008253A (es)	2009-10-12	Derivados de 2-aminopiridina utiles como inhibidores de cinasa.
WO2007095188A3 (en)	2007-10-25	Dihydrodiazepines useful as inhibitors of protein kinases
MX2009009592A (es)	2009-11-10	Aminopiridinas utiles como inhibidores de proteinas cinasas.
TW200514776A (en)	2005-05-01	Aminotriazole compounds useful as inhibitors of protein kinases
UA84930C2 (ru)	2008-12-10	Пиррольные соединения как ингибиторы протеинкиназ erk, их синтез и соответствующие промежуточные соединения
ATE542814T1 (de)	2012-02-15	Pyrazinkinaseinhibitoren
ZA200702645B (en)	2008-08-27	Diaminotriazole compounds useful as protein kinase inhibitors
WO2007139816A3 (en)	2008-01-17	Thiophene-carboxamides useful as inhibitors of protein kinases
WO2007015923A8 (en)	2008-04-03	Benzimidazoles useful as inhibitors of protein kinases
IL179206A0 (en)	2007-03-08	Pyrrolylpyrimidine derivatives and pharmaceutical compositions containing the same
MX2009005231A (es)	2009-06-19	Composiciones utiles como inhibidores de proteina cinasa.

Legal Events

Date	Code	Title	Description
2016-05-27	PC	Patent ceased (i.e. patent has lapsed due to the failure to pay the renewal fee)	Effective date: 20151104